CHAD THERAPEUTICS INC Form SC 13G/A February 13, 2008

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS
FILED PURSUANT TO RULE 13d-1(b), (c) AND (d)
AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b)

(Amendment No. 1) *

CHAD THERAPEUTICS, INC.
(Name of Issuer)
Common Stock, \$.0.01 par value per share
(Title of Class of Securities)
157228107
(CUSIP Number)
December 31, 2007
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
[] Rule 13d-1(b) [X] Rule 13d-1(c) [] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the

for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 157228107

(1)	1) Names of Reporting Persons. I.R.S. (entities only):	Identification Nos. of Above Persons
	Laurus Master Fund, Ltd. 98-0337673	
(2)	2) Check the Appropriate Box if a Membe (a) [] (b) [X]	er of a Group (See Instructions)
(3)	3) SEC Use Only	
(4)	4) Citizenship or Place of Organizat	ion: Cayman Islands
	umber of Shares Beneficially Owned by Each Reporting Person With (5)	Sole Voting Power: 0*
	(6)	Shared Voting Power: 1,016,982*
	(7)	Sole Dispositive Power: 0*
	(8)	Shared Dispositive Power: 1,016,982*
	10) Check if the Aggregate Amount in Row Instructions): [X]	
(12	12) Type of Reporting Person (See Instru	ctions): CO, HC
"Sha "Con qua Cap toga "Wa	Shares") outstanding of Chad Therapeutic Company"), as disclosed in the Company' uarterly period ended September 30, 20 apital Corporation ("Calliope") and V ogether with Calliope, the "Investors") Warrant") to acquire 976,744 Shares, a	on stock, \$0.01 par value per share (the es, Inc., a California corporation (the s Quarterly Report on Form 10-Q for the 107. As of December 31, 2007, Calliope Valens U.S. SPV I, LLC ("Valens US", and collectively held (i) a warrant (the 1st an exercise price of \$1.24 per Share, a) a secured convertible term note (the

pursuant to the terms of the applicable instrument). Calliope is a wholly owned subsidiary of Laurus Master Fund, Ltd. which is managed by Laurus Capital Management, LLC. Valens US is managed by Valens Capital Management, LLC. Eugene Grin and David Grin, through other entities, are the controlling principals of Laurus Capital Management, LLC and Valens Capital Management, LLC and share voting and investment power over the securities owned by the Investors reported in this Schedule 13G, as amended.

CUSI	P No.	1572281	07									
(1)		of Repo	rting Pers	sons.	I.R.S.	•	Identif:	ication	Nos	. of	Above	Persons
		237865	ital Corpo	oration	n 							
(2)	(a	the App) []) [X]	ropriate I	3ox if	a Membe:	er 	of a Gro	oup (Se	e Inst	truct	tions)	
(3)	SE	C Use On	ly									
(4)	Ci	tizenshi	o or Place	e of Or	rganizat:	i.		aware				
			eneficial g Person N	_) 5	Sole Vot:	ing Pow				0*
					(6)) 5	Shared Vo	oting P	ower:		1,	016,982*
					(7)		Sole Disp	positiv	e Powe	er:		0*
					(8)		Shared Di			ower		016,982*
(9)	Aggre	 gate Amo	unt Benef	icially	Owned b		y Each Re	 eportin	g Per	son:		
		1,016,9	82									
(10)		if the uctions)	Aggregate : [X]	Amount	in Row	w	(9) Exclı	ıdes Ce	rtain	Sha	res (S	ee
(11)	Perce		ass Repres					(9) : 9	.99%*			
(12)	Type	of Repor	ting Perso	on (See	e Instru	ıct	cions):	CO				
			000 shares									

"Company"), as disclosed in the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2007. As of December 31, 2007, Calliope Capital Corporation ("Calliope") and Valens U.S. SPV I, LLC ("Valens US", and

together with Calliope, the "Investors") collectively held (i) a warrant (the "Warrant") to acquire 976,744 Shares, at an exercise price of \$1.24 per Share, subject to certain adjustments, and (ii) a secured convertible term note (the "Note") in the aggregate principal amount of \$750,000, which is convertible into Shares at a conversion rate of \$1.18 per Share, subject to certain adjustments. The Warrant and Note contain an issuance limitation prohibiting the Investors from exercising or converting those securities to the extent that such exercise would result in beneficial ownership by the Investors of more than 9.99% of the Shares then issued and outstanding (the "Issuance Limitation"). The Issuance Limitation may be waived by the Investors upon at least 61 days prior notice to the Company and shall automatically become null and void (i) following notice to the Issuer of the occurrence and during the continuance of an event of default (as defined in and pursuant to the terms of the applicable instrument), or (ii) upon receipt by the Investors of a Notice of Redemption (as defined in an pursuant to the terms of the applicable instrument). Calliope is a wholly owned subsidiary of Laurus Master Fund, Ltd. which is managed by Laurus Capital Management, LLC. Valens US is managed by Valens Capital Management, LLC. Eugene Grin and David Grin, through other entities, are the controlling principals of Laurus Capital Management, LLC and Valens Capital Management, LLC and share voting and investment power over the securities owned by the Investors reported in this Schedule 13G, as amended.

CUSI	P No.	157228107						
(1)		of Reporting Persons. I.	.R.S.	Identi	fication	Nos. o	f Above	Persons
		us Capital Management, LLC 150669						
(2)	(a	the Appropriate Box if a N) []) [X]	Membei	of a 0	Group (See	Instru	ctions)	
(3)	SE(C Use Only						
(4)	Ci [.]	tizenship or Place of Orgar	nizati	ion: De	elaware			
		Shares Beneficially Owned Reporting Person With	(5)	Sole Vo	oting Powe			0*
			(6)		Voting Po	wer:	1,	 016 , 982*
			(7)	Sole Di	spositive	Power:		0*
			(8)		Dispositi	ve Powe:	r: 1,	016,982*
(9)	Aggre	gate Amount Beneficially Ov	wned k	oy Each	Reporting	Person	 :	
		1,016,982						

	Lugar Filling. OFFAD THE	TALEUTIOS INO - FUITI SO 130	A/A
(11)	Percent of Class Represented by	Amount in Row (9): 9.99%	
(12)	Type of Reporting Person (See In	structions): 00	
"Shar Capit toge "War Subj "Not Shar The from woul Shar Limit the (as upon purs subs Mana Grin Laur voti	ased on 10,180,000 shares of the cares") outstanding of Chad Therape mpany"), as disclosed in the Comparation ("Calliope") as tall Corporation ("Calliope") as ther with Calliope, the "Investo carnt") to acquire 976,744 Shares ject to certain adjustments, and ite") in the aggregate principal amoves at a conversion rate of \$1.18; Warrant and Note contain an issuant exercising or converting those and exercising or converting those and result in beneficial ownership tes then issued and outstanding thation may be waived by the Investors of the occurrence and dur defined in and pursuant to the test of the applicability of Laurus Master Fund, agement, LLC. Valens US is managed and David Grin, through other entry Capital Management, LLC and and and investment power over the this Schedule 13G, as amended.	utics, Inc., a California co any's Quarterly Report on Form, 2007. As of December 31, 2 nd Valens U.S. SPV I, LLC ("V rs") collectively held (i), , at an exercise price of \$1 (ii) a secured convertible ount of \$750,000, which is comper Share, subject to certain nee limitation prohibiting securities to the extent that by the Investors of more that (the "Issuance Limitation"). stors upon at least 61 days precome null and void (i) following the continuance of an every rms of the applicable instrumance of the applicable instrumance and the instrument of the applicable instrument of the applic	rporation (the m 10-Q for the 007, Calliope alens US", and a warrant (the .24 per Share, term note (the nvertible into n adjustments. the Investors such exercise n 9.9% of the The Issuance rior notice to wing notice to ent of default ent), or (ii) defined in an a wholly owned aurus Capital t, LLC. Eugene principals of LLC and share
CUSI	P No. 157228107		
(1)	Names of Reporting Persons. I.: (entities only): Valens U.S. SPV I, LLC 20-8903266	R.S. Identification Nos. of	Above Persons
(2)	Check the Appropriate Box if a Market (a) [] (b) [X]	ember of a Group (See Instruc	tions)
(3)	SEC Use Only		
(4)	Citizenship or Place of Organ	ization: Delaware	
	per of Shares Beneficially Owned 7 Each Reporting Person With	(5) Sole Voting Power:	0*
		(6) Shared Voting Power:	1,016,982*

	(7)	Sole Dispositive Power: 0*
	(8)	Shared Dispositive Power: 1,016,982*
(9)	Aggregate Amount Beneficially Owned	by Each Reporting Person:
	1,016,982	
(10)	Check if the Aggregate Amount in Row Instructions): [X]	(9) Excludes Certain Shares (See
(11)	Percent of Class Represented by Amou	unt in Row (9): 9.99%*
(12)	Type of Reporting Person (See Instru	

* Based on 10,180,000 shares of the common stock, \$0.01 par value per share (the "Shares") outstanding of Chad Therapeutics, Inc., a California corporation (the "Company"), as disclosed in the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2007. As of December 31, 2007, Calliope Capital Corporation ("Calliope") and Valens U.S. SPV I, LLC ("Valens US", and together with Calliope, the "Investors") collectively held (i) a warrant (the "Warrant") to acquire 976,744 Shares, at an exercise price of \$1.24 per Share, subject to certain adjustments, and (ii) a secured convertible term note (the "Note") in the aggregate principal amount of \$750,000, which is convertible into Shares at a conversion rate of \$1.18 per Share, subject to certain adjustments. The Warrant and Note contain an issuance limitation prohibiting the Investors from exercising or converting those securities to the extent that such exercise would result in beneficial ownership by the Investors of more than 9.99% of the Shares then issued and outstanding (the "Issuance Limitation"). The Issuance Limitation may be waived by the Investors upon at least 61 days prior notice to the Company and shall automatically become null and void (i) following notice to the Issuer of the occurrence and during the continuance of an event of default (as defined in and pursuant to the terms of the applicable instrument), or (ii) upon receipt by the Investors of a Notice of Redemption (as defined in an pursuant to the terms of the applicable instrument). Calliope is a wholly owned subsidiary of Laurus Master Fund, Ltd. which is managed by Laurus Capital Management, LLC. Valens US is managed by Valens Capital Management, LLC. Eugene Grin and David Grin, through other entities, are the controlling principals of Laurus Capital Management, LLC and Valens Capital Management, LLC and share voting and investment power over the securities owned by the Investors reported in this Schedule 13G, as amended.

CUSIP No. 157228107

(1) Names of Reporting Persons. I.R.S. Identification Nos. of Above Persons (entities only):

Valens Capital Management, LLC 20-8903345

(2)	(a)	the App: [] [X]	copriate Box i	.f a Membe.	r of a (Group (See Instruct	cions)
(3)	SEC	Use On	_				
(4)	Cit	izenshi	o or Place of	Organizat	ion: De	elaware	
			eneficially Ow g Person With		Sole Vo	oting Power:	0 *
				(6)		Voting Power:	
				(7)	Sole D	spositive Power:	0 *
				(8)	Shared	Dispositive Power:	1,016,982*
(9)	 Aggreg					Reporting Person:	
		1,016,98	32				
(10)		if the A		nt in Row	(9) Exc	cludes Certain Shar	res (See
(11)	Percen	t of Cla	ass Represente	ed by Amou:	nt in Ro	ow (9): 9.99%*	
(12)	Type o	f Report	ing Person (S	See Instru	ctions)	: 00	

^{*} Based on 10,180,000 shares of the common stock, \$0.01 par value per share (the "Shares") outstanding of Chad Therapeutics, Inc., a California corporation (the "Company"), as disclosed in the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2007. As of December 31, 2007, Calliope Capital Corporation ("Calliope") and Valens U.S. SPV I, LLC ("Valens US", and together with Calliope, the "Investors") collectively held (i) a warrant (the "Warrant") to acquire 976,744 Shares, at an exercise price of \$1.24 per Share, subject to certain adjustments, and (ii) a secured convertible term note (the "Note") in the aggregate principal amount of \$750,000, which is convertible into Shares at a conversion rate of \$1.18 per Share, subject to certain adjustments. The Warrant and Note contain an issuance limitation prohibiting the Investors from exercising or converting those securities to the extent that such exercise would result in beneficial ownership by the Investors of more than 9.99% of the Shares then issued and outstanding (the "Issuance Limitation"). The Issuance Limitation may be waived by the Investors upon at least 61 days prior notice to the Company and shall automatically become null and void (i) following notice to the Issuer of the occurrence and during the continuance of an event of default (as defined in and pursuant to the terms of the applicable instrument), or (ii) upon receipt by the Investors of a Notice of Redemption (as defined in an pursuant to the terms of the applicable instrument). Calliope is a wholly owned subsidiary of Laurus Master Fund, Ltd. which is managed by Laurus Capital Management, LLC. Valens US is managed by Valens Capital Management, LLC. Eugene Grin and David Grin, through other entities, are the controlling principals of Laurus Capital Management, LLC and Valens Capital Management, LLC and share voting and investment power over the securities owned by the Investors reported in this Schedule 13G, as amended.

CUSI	P No. 157228107			
(1)	Names of Reporting Persons. (entities only):	[.R.S.	Identification Nos. of P	Above Persons
	David Grin			
(2)	Check the Appropriate Box if a (a) [] (b) [X]	Membe	r of a Group (See Instructi	ons)
(3)	SEC Use Only			
(4)	Citizenship or Place of Orga	anizat	ion: Israel	
	er of Shares Beneficially Owned Each Reporting Person With	(5)	Sole Voting Power:	0 *
			Shared Voting Power:	1,016,982*
		(7)	Sole Dispositive Power:	0 *
		(8)	Shared Dispositive Power:	
 (9)	Aggregate Amount Beneficially (owned	 oy Each Reporting Person:	
	1,016,982			
(10)	Check if the Aggregate Amount instructions): [X]	in Row	(9) Excludes Certain Share	es (See
(11)	Percent of Class Represented by	/ Amou:	nt in Row (9): 9.99%	
(12)	Type of Reporting Person (See 1	[nstru	ctions): IN	
"Sha "Com quar Capi toge "War subj "Not Shar The from	sed on 10,180,000 shares of the res") outstanding of Chad Therap pany"), as disclosed in the Conterly period ended September 3 tal Corporation ("Calliope") ther with Calliope, the "Invest rant") to acquire 976,744 Share ect to certain adjustments, are") in the aggregate principal are at a conversion rate of \$1.18 Warrant and Note contain an issue exercising or converting those descriptions and result in boneficial expressions.	peutic mpany' 30, 20 and V cors") es, a nd (ii amount 3 per uance e secu	s, Inc., a California corp s Quarterly Report on Form 07. As of December 31, 200 alens U.S. SPV I, LLC ("Val collectively held (i) a t an exercise price of \$1.2 a secured convertible to of \$750,000, which is conv Share, subject to certain limitation prohibiting to rities to the extent that s	poration (the 10-Q for the 10-Q for the 107, Calliope ens US", and warrant (the 124 per Share, erm note (the vertible into adjustments. The Investors such exercise

Shares then issued and outstanding (the "Issuance Limitation"). The Issuance Limitation may be waived by the Investors upon at least 61 days prior notice to the Company and shall automatically become null and void (i) following notice to the Issuer of the occurrence and during the continuance of an event of default (as defined in and pursuant to the terms of the applicable instrument), or (ii) upon receipt by the Investors of a Notice of Redemption (as defined in an pursuant to the terms of the applicable instrument). Calliope is a wholly owned subsidiary of Laurus Master Fund, Ltd. which is managed by Laurus Capital Management, LLC. Valens US is managed by Valens Capital Management, LLC. Eugene Grin and David Grin, through other entities, are the controlling principals of Laurus Capital Management, LLC and Valens Capital Management, LLC and share voting and investment power over the securities owned by the Investors reported in this Schedule 13G, as amended.

CUSI	P No.	15722810	7							
(1)		of Repor	_	sons.	I.R.S.	Ident	ificatior	n Nos. o	f Above	Persons
	Euge	ne Grin								
(2)	(a	the Appr	opriate E	Box if a	Member	of a	Group (Se	e Instru	ctions)	
(3)	SE	C Use Onl	У							
(4)	Ci	tizenship	or Place	e of Org	ganizati	on: U	nited Sta	ites		
		Shares Be Reporting		-		Sole V	oting Pov	ver:		0*
					(6)		Voting E			016 , 982*
					(7)	Sole D	ispositiv	e Power:		0*
					(8)		Disposit			016 , 982*
(9)	Aggre	gate Amou	nt Benefi	cially	Owned k	y Each	Reportir	g Person	:	
		1,016,98	2							
(10)		if the A		Amount	in Row	(9) Ex	cludes Ce	ertain Sh	ares (S	ee
(11)	Perce	nt of Cla	ss Repres	sented b	y Amour	nt in R	ow (9): 9	0.99%		
(12)	Туре	of Report	ing Perso	on (See	Instruc	ctions)	: IN			

* Based on 10,180,000 shares of the common stock, \$0.01 par value per share (the "Shares") outstanding of Chad Therapeutics, Inc., a California corporation (the "Company"), as disclosed in the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2007. As of December 31, 2007, Calliope Capital Corporation ("Calliope") and Valens U.S. SPV I, LLC ("Valens US", and together with Calliope, the "Investors") collectively held (i) a warrant (the "Warrant") to acquire 976,744 Shares, at an exercise price of \$1.24 per Share, subject to certain adjustments, and (ii) a secured convertible term note (the "Note") in the aggregate principal amount of \$750,000, which is convertible into Shares at a conversion rate of \$1.18 per Share, subject to certain adjustments. The Warrant and Note contain an issuance limitation prohibiting the Investors from exercising or converting those securities to the extent that such exercise would result in beneficial ownership by the Investors of more than 9.99% of the Shares then issued and outstanding (the "Issuance Limitation"). The Issuance Limitation may be waived by the Investors upon at least 61 days prior notice to the Company and shall automatically become null and void (i) following notice to the Issuer of the occurrence and during the continuance of an event of default (as defined in and pursuant to the terms of the applicable instrument), or (ii) upon receipt by the Investors of a Notice of Redemption (as defined in an pursuant to the terms of the applicable instrument). Calliope is a wholly owned subsidiary of Laurus Master Fund, Ltd. which is managed by Laurus Capital Management, LLC. Valens US is managed by Valens Capital Management, LLC. Eugene Grin and David Grin, through other entities, are the controlling principals of Laurus Capital Management, LLC and Valens Capital Management, LLC and share voting and investment power over the securities owned by the Investors reported in this Schedule 13G, as amended.

CUSIP No. 157228107

Item 1(a). Name Of Issuer: Chad Therapeutics, Inc.

Item 1(b). Address of Issuer's Principal Executive Offices:

21622 Plummer Street Chatsworth, California 91311

Item 2(a). Name of Person Filing:

Laurus Master Fund, Ltd.

This Schedule 13G, as amended, is also filed on behalf of Calliope Capital Corporation, a Delaware corporation and a wholly owned subsidiary of Laurus Master Fund, Ltd., Laurus Capital Management, LLC, a Delaware limited liability company, Valens U.S. SPV I, LLC, a Delaware limited liability company, Valens Capital Management, LLC, a Delaware limited liability company, Eugene Grin and David Grin. Laurus Capital Management, LLC manages Laurus Master Fund, Ltd. Valens Capital Management, LLC manages Valens U.S. SPV I, LLC. Eugene Grin and David Grin, through other entities, are the controlling principals of Laurus Capital Management, LLC and Valens Capital Management, LLC and share sole voting and investment power over the shares owned by Calliope Capital Corporation and Valens U.S. SPV I, LLC. Information related to each of Laurus Capital Management, LLC, Valens Capital Management, LLC, Calliope Capital Corporation, Valens U.S. SPV I, LLC, Eugene Grin and David Grin is set forth on Appendix A hereto.

Item 2(b). Address of Principal Business Office or, if None, Residence:

c/o Laurus Capital Management, LLC,
335 Madison Avenue, 10th Floor
New York, NY 10017

Item 2(c). Citizenship:

Cayman Islands

Item 2(d). Title of Class of Securities: Common Stock ("Common Stock")

Item 2(e). CUSIP No.: 157228107

Item 3. If This Statement Is Filed Pursuant to Sections 240.13d-1(b) or 240.13d-2(b) or (c), check whether the Person Filing is a:

Not Applicable.

Item 4. Ownership

(a) Amount Beneficially Owned: 1,016,982

(b) Percent of Class: 9.99%

(c) Number of Shares as to which the person has:

(i) sole power to vote or to direct the vote 0*

(ii) shared power to vote or to direct the vote 1,016,982*

(iii) sole power to dispose or to direct the disposition of $$\operatorname{\textsc{0}}^{\star}$$

^{*} Based on 10,180,000 shares of the common stock, \$0.01 par value per share (the "Shares") outstanding of Chad Therapeutics, Inc., a California corporation (the "Company"), as disclosed in the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2007. As of December 31, 2007, Calliope Capital Corporation ("Calliope") and Valens U.S. SPV I, LLC ("Valens US", and together with Calliope, the "Investors") collectively held (i) a warrant (the "Warrant") to acquire 976,744 Shares, at an exercise price of \$1.24 per Share, subject to certain adjustments, and (ii) a secured convertible term note (the "Note") in the aggregate principal amount of \$750,000, which is convertible into Shares at a conversion rate of \$1.18 per Share, subject to certain adjustments. The Warrant and Note contain an issuance limitation prohibiting the Investors from exercising or converting those securities to the extent that such exercise would result in beneficial ownership by the Investors of more than 9.99% of the Shares then issued and outstanding (the "Issuance Limitation"). The Issuance Limitation may be waived by the Investors upon at least 61 days prior notice to the Company and shall automatically become null and void (i) following notice to the Issuer of the occurrence and during the continuance of an event of default (as defined in and pursuant to the terms of the applicable instrument), or (ii) upon receipt by the Investors of a Notice of Redemption (as defined in an

pursuant to the terms of the applicable instrument). Calliope is a wholly owned subsidiary of Laurus Master Fund, Ltd. which is managed by Laurus Capital Management, LLC. Valens US is managed by Valens Capital Management, LLC. Eugene Grin and David Grin, through other entities, are the controlling principals of Laurus Capital Management, LLC and Valens Capital Management, LLC and share voting and investment power over the securities owned by the Investors reported in this Schedule 13G, as amended.

Item 5. Ownership of Five Percent or Less of a Class

Not applicable

Item 6. Ownership of More Than Five Percent on Behalf of Another Person

Not Applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

Not Applicable.

Item 8. Identification and Classification of Members of the Group

Not Applicable.

Item 9. Notice of Dissolution of Group

Not Applicable.

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 14, 2008

Date

LAURUS MASTER FUND, LTD.

By: /s/ David Grin

Name: David Grin Title: Director

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)

CUSIP No. 284739109

APPENDIX A

A. Name: Laurus Capital Management, LLC, a Delaware limited

liability company

Address: 335 Madison Avenue, 10th Floor

New York, New York 10017

Place of

Organization: Delaware

B. Name: Calliope Capital Corporation, a Delaware

corporation

Address: c/o Laurus Capital Management, LLC

335 Madison Avenue, 10th Floor

New York, New York 10017

Place of

Organization: Delaware

C. Name: Valens U.S. SPV I, LLC, a Delaware limited liability

company

Address: c/o Laurus Capital Management, LLC

335 Madison Avenue, 10th Floor

New York, New York 10017

Place of

Organization: Delaware

D. Name: Valens Capital Management, LLC, a Delaware limited

liability company

Address: c/o Laurus Capital Management, LLC

335 Madison Avenue, 10th Floor

New York, New York 10017

Place of

Organization: Delaware

E. Name: David Grin

Business 335 Madison Avenue, 10th Floor

Address: New York, New York 10017

Principal Director of Laurus Master Fund, Ltd. Principal Occupation:

Principal of Laurus Capital Management, LLC

Citizenship: Israel

F. Name: Eugene Grin

Business 335 Madison Avenue, 10th Floor

Address: New York, New York 10017

Director of Laurus Master Fund, Ltd. Principal Occupation:

Principal of Laurus Capital Management, LLC

Citizenship: United States

CUSIP No. 157228107

Each of Calliope Capital Corporation, Laurus Capital Management, LLC, Valens U.S. SPV I, LLC, Valens Capital Management, LLC, Eugene Grin and David Grin hereby agree, by their execution below, that the Schedule 13G (as amended) to which this Appendix A is attached is filed on behalf of each of them, respectively.

Calliope Capital Corporation

/s/ Eugene Grin

Eugene Grin

President, Chairman, Secretary

February 14, 2008

Laurus Capital Management, LLC

/s/ David Grin

David Grin Principal

February 14, 2008

Valens U.S. SPV I, LLC

Valens Capital Management, LLC

By: Valens Capital Management, LLC

Individually and on behalf of Valens U.S. SPV I, LLC

/s/	David Grin	
	David Grin February 14,	2008
/s/	Eugene Grin	
	Eugene Grin February 14,	2008